Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

Making in 2025. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the top performers. Terns Pharmaceuticals climbed by ...

At the recent American Society of Hematology annual meeting, researchers presented real-world outcomes for patients with blast-phase chronic myeloid leukemia (CML) using data from a multi-institution ...

Leukemia is a blood cancer with abnormal white blood cell overproduction, affecting red blood cells and platelets, leading to anemia and infection risks. Diagnosis involves blood tests, bone marrow ...

When it comes to selecting a cost-effective, first-line tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML), consider the treatment goal. For survival, generic imatinib ...

Medically reviewed by Archana Sharma, DO Key Takeaways Leukemia starts in the bone marrow and spreads through the ...

The major molecular response rate was 68% with asciminib and 49% with IS-TKIs (difference, 19% [95% CI, 10-28]; P .001). The Food and Drug Administration (FDA) has granted accelerated approval to ...

(a) Peripheral blood smear in a patient with the chronic phase of chronic myeloid leukemia (CML) before treatment; (b) Detection of BCR::ABL1 fusion gene, p210 by RNA sequencing; (c) Peripheral blood ...

76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% ...

Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...